Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07386314

Motor and Cognitive Telerehabilitation for Acquired Brain Injury

The overall objective of the study is to compare upper limb cognitive and motor rehabilitation programs delivered via tele-rehabilitation and in-person, in order to evaluate their overall impact on the rehabilitation process of subjects with GCA outcomes at the end of the subacute phase.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

The study is a controlled clinical trial aimed at evaluating the efficacy and feasibility of cognitive and motor rehabilitation programs delivered in person or via tele-rehabilitation. Sixty-two subjects, aged 18 to 75, of both sexes, will be consecutively enrolled at the three participating centers. The sample size was calculated assuming a change of 15 points (standard deviation 20) on the Brief Neuropsychological Examination (BNE), with alpha = 0.05, beta = 0.2, and a power of 80%. A 10% margin was added to the resulting number (28 subjects per group) for potential dropouts. The ENB was chosen as the primary measure because, validated in the Italian population, it allows for a comprehensive, multidomain assessment that is sensitive to changes in the main cognitive domains (attention, memory, language, executive and praxic functions), also allowing for the evaluation of treatment efficacy over time, with short administration times and good tolerability in patients with GCA outcomes. Recent multicenter studies have confirmed its reliability and clinical relevance in this population. Subjects will be assigned to two treatment groups using block randomization, stratified by age, gender, and baseline functional level. This procedure was adopted to reduce potential bias and ensure greater comparability between groups. However, a geographical restriction will be maintained: patients unable to physically access the facility will be included in the tele-rehabilitation group (TG), but will follow the same stratification and randomization procedure, ensuring methodological consistency and allowing for dedicated sensitivity analyses.

The in-person treatment group (GP) will complete 50-minute sessions, three times a week for eight weeks, at the rehabilitation center. The tele-rehabilitation treatment group (TG) will complete a similar program at home, with the same frequency and duration, via dedicated platforms.

Sixty-two subjects (18-75 years old, both genders) will be consecutively enrolled at the three participating centers upon discharge from hospital rehabilitation. Patients will be assigned equally to the two groups (in-person treatment and tele-rehabilitation) using block randomization stratified by age, gender, and functional level.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Outcome of Severe Acquired Brain Injury (GAI) of various etiologies;

  • Age between 18 and 75 years
  • Level of Cognitive Functioning (LCF) at discharge from the hospital ward >= 6;
  • One or more neuropsychological deficits in the areas of attention, memory, language, and executive functions;
  • Possible upper limb motor deficit;
  • Absence of general clinical complications that could interfere with rehabilitation treatment;
  • Cognitive and language functions sufficient to understand the instructions provided and give consent -

Exclusion criteria

  • Level of Cognitive Functioning (LCF) at discharge from hospitalization ward < 6;
  • Presence of previous deficits in neuropsychological and motor functions prior to the acute event;
  • Vulnerable subjects or those in emergency situations
  • Failure to provide informed consent.
  • Pregnant or intending to become pregnant during the enrollment period -

Treatment and study plan

Tele-rehabilitation

Device

The telerehabilitation treatment group (GT) will receive a similar motor and cognitive treatment program at home using the VRRS HomeKit device (Khymeia, Padua, Italy), another certified Class 1 medical device.

Group Presence

Device

Patients in the in-person treatment group (GP) will undergo 50-minute sessions, three times a week, for a total of eight weeks using VRRS virtual reality systems (Khymeia, Padua, Italy), certified Class 1 medical devices. The first four weeks of treatment will be conducted with VRRS EVO, while the following four weeks will be conducted with VRRS Physio, with exercises designed to improve various cognitive and motor domains of the upper limb.

Primary outcomes

  1. Brief Neuropshychological Examination

    Time frame: Pre-intervetion and immediately after 8 weeks of intervention

  2. Flug Meyer Upper Extremity Scale

    Time frame: Pre-intervetion and immediately after 8 weeks of intervention

Secondary outcomes

  1. System Usability Scale

    Time frame: Pre-intervetion and immediately after 8 weeks of intervention

  2. Client Satisfaction Questionnaire-8 Total scores range from 8 to 32, with the higher number indicating greater satisfaction

    Time frame: Pre-intervetion and immediately after 8 weeks of intervention

Study contacts

Contact information is provided by the study sponsor or research team.

Federico Posteraro

CONTACT

[email protected]

+3905746057061

Sponsors and collaborators

Lead sponsor

Azienda USL Toscana Nord Ovest

Other

Collaborators

  • IRCCS Bonino Pulejo
  • Istituto S.Anna Crotone

Registry information

Acronym: TELEGCA

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Feb 4, 2026
Registry last updated
Feb 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.